Abstract PS9-40: Multiple activities improve oncologists' knowledge and competence with CDK4/6 inhibitors in HR+ breast cancer over time

Abstract Background:Recently, CDK4/6 inhibitors have revolutionized the care of patients with hormone receptor (HR)-positive, HER2-negative breast cancer, improving survival outcomes. Already, there are multiple CDK4/6 inhibitors available that differ in their pharmacologic features, reported outcomes, therapeutic indications, and adverse event profiles. As data from clinical trials or subgroup analyses become available, landmark trials are published, and guideline recommendations or clinical utility of these therapies change, continuing medical education (CME) for oncologists is necessary to facilitate timely and accurate translation of evidence to their clinical practice. Methods: A series of 5 CME-certified activities were launched to educate oncologists on CDK4/6 therapies in HR-positive advanced breast cancer following data releases from ESMO 2019 through SABCS 2019. Education followed adult learning principles starting with a goal of increasing awareness on novel data and then integrating these agents into clinical practice, including adverse event management. Panel discussions were utilized to provide multiple faculty perspectives and clinical anecdotes. Effectiveness was analyzed using 3 multiple-choice and 1 self-efficacy question measuring knowledge, competence, and confidence, presented as pre-/post-CME repeated pairs for each of the activities. Oncologists who completed both the pre- and post-CME questions were included in analysis and MeNemar’s tests were conducted to assess statistical significance of the results with p < .05 being considered significant. The 5 CME activities launched from September 2019 through December 2019.Results: As of 6/9/2020, 6,037 global physicians had participated in the activities including 2,511 oncologists. 64% of the oncologists identified themselves as practicing in a community setting and 82% of them intended to modify their treatment plans as a result of education. Analyses from 3 activities using data from n=356-458 oncologists found significant improvements in: •Knowledge of clinical trial safety and efficacy data with CDK4/6 inhibitors (% pre correct 65% vs. % post correct 73%; p < .001) •Competence implementing personalized CDK4/6 inhibitor for a patient (% pre correct 74% vs. % post correct 84%; p < .001) •Knowledge of adverse events with CDK4/6 inhibitors (% pre correct 63% vs. % post correct 74%; p <.001)•Confidence personalizing and implementing CDK4/6 inhibitor therapy in practice (% pre confident 37% vs. % post confident 50%, p< .001)Conclusions: This series of live and online, expert-led, CME-certified educational activities resulted in significant improvements in knowledge, competence, and confidence among oncologists regarding the use of CDK4/6 inhibitor therapies in the management of advanced HR-positive breast cancer. These results also highlight the effectiveness of on-demand education to facilitate information transfer from conferences to clinical practice. Grantors:This educational initiative was supported through educational grants from Lilly. Citation Format: Kinjal Parikh, Nabil Dorkhom, Pan Chen, Davecia Ragoonath Cameron, Mindy Tanzola, Pamela Peters, Sara Tolaney. Multiple activities improve oncologists' knowledge and competence with CDK4/6 inhibitors in HR+ breast cancer over time [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-40.